Compare Marriott International Inc (MAR) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marriott International Inc vs Tango Therapeutics Inc. — how do they compare? Marriott International Inc trades at $374.99 (market cap $96.96B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Marriott International Inc is far larger — about 25.9× Tango Therapeutics Inc.'s market cap, and Marriott International Inc pays a 0.79% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marriott International Inc for 164 Days and Tango Therapeutics Inc. for 0 Days on average.
| MAR | TNGX | |
|---|---|---|
Market Cap | $96.96B | $3.74B |
Volume | 1,354,129 | 3,438,781 |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $32.90 |
52-Week Low | $259.04 | $7.50 |
Typical Hold Time | 164 Days | 0 Days |
Enterprise Value | $114.27B | $2.76B |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $371.50, up 0.6% today, with a bullish technical outlook supported by moving averages and strong institutional interest. The company reported revenue of $26.19B in 2025, with net income of $2.60B, though it missed Q4 2025 EPS estimates. Valuation ratios like P/E of 38.46 and P/S of 3.71 indicate a premium, while debt levels have risen to 58.83% of assets in 2025. Recent news highlights partnerships and dividend declarations, reinforcing its travel sector resilience.
The stock offers growth potential from sustained travel demand and strategic expansions, but faces risks from high leverage and economic sensitivity. Analysts are mostly neutral with a consensus price target of $388.93, suggesting modest upside. Investors should weigh solid profitability against valuation concerns and macroeconomic headwinds.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
